PriceTargets.com logo

Omnicell - OMCL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $42.20
  • Forecasted Upside: 53.85%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$27.43 As of 04/24/2024 06:22 PM ET
▼ -1 (-3.52%)

This chart shows the closing price for OMCL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Omnicell Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMCL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMCL

Analyst Price Target is $42.20
▲ +53.85% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Omnicell in the last 3 months. The average price target is $42.20, with a high forecast of $75.00 and a low forecast of $26.00. The average price target represents a 53.85% upside from the last price of $27.43.

This chart shows the closing price for OMCL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in Omnicell. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2024BenchmarkLower TargetBuy ➝ Buy$42.00 ➝ $38.00Low
2/9/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$28.00 ➝ $26.00Low
1/3/2024BarclaysInitiated CoverageUnderweight$33.00Low
11/3/2023BTIG ResearchDowngradeBuy ➝ NeutralLow
11/3/2023Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$39.00 ➝ $28.00Low
11/3/2023Piper SandlerUpgradeNeutral ➝ Overweight$70.00 ➝ $39.00Low
10/3/2023BenchmarkLower TargetBuy ➝ Buy$88.00 ➝ $70.00Low
9/26/2023Wells Fargo & CompanyLower TargetUnderweight ➝ Underweight$56.00 ➝ $39.00Low
8/4/2023KeyCorpLower TargetOverweight ➝ Overweight$80.00 ➝ $75.00Low
8/2/2023BenchmarkReiterated RatingBuy ➝ Buy$88.00N/A
8/2/2023Piper SandlerDowngradeOverweight ➝ Neutral$66.00 ➝ $70.00Low
7/20/2023Wells Fargo & CompanyDowngradeOverweight ➝ Underweight$65.00 ➝ $56.00N/A
7/13/2023KeyCorpBoost Target$70.00 ➝ $80.00Low
6/15/2023BenchmarkBoost Target$68.00 ➝ $88.00Low
5/3/2023KeyCorpBoost Target$65.00 ➝ $70.00Low
3/2/2023KeyCorpLower TargetOverweight$70.00 ➝ $65.00Low
2/27/2023BenchmarkUpgradeHold ➝ Buy$68.00Low
2/2/2023KeyCorpLower TargetOverweight$75.00 ➝ $70.00Low
1/27/2023SVB LeerinkReiterated RatingMarket PerformLow
1/27/2023Piper SandlerBoost TargetOverweight$55.00 ➝ $66.00Low
1/24/2023Wells Fargo & CompanyLower TargetOverweight$71.00 ➝ $65.00Low
12/14/2022Piper SandlerLower Target$55.00Low
11/18/2022JPMorgan Chase & Co.Lower TargetNeutral$140.00 ➝ $57.00Low
11/4/2022Wells Fargo & CompanyLower TargetOverweight$158.00 ➝ $71.00Low
11/3/2022Craig HallumLower Target$185.00 ➝ $75.00N/A
11/3/2022BenchmarkDowngradeBuy ➝ HoldN/A
11/3/2022BTIG ResearchLower TargetBuy$160.00 ➝ $75.00N/A
11/3/2022KeyCorpLower TargetOverweight$130.00 ➝ $75.00N/A
11/3/2022SVB LeerinkLower TargetMarket Perform$117.00 ➝ $54.00N/A
11/2/2022Piper SandlerLower Target$145.00 ➝ $58.00N/A
9/23/2022BenchmarkLower TargetBuy$170.00 ➝ $157.00Low
9/21/2022BTIG ResearchLower TargetBuy$175.00 ➝ $160.00Low
9/21/2022Piper SandlerLower TargetOverweight$150.00 ➝ $145.00Low
9/15/2022KeyCorpInitiated CoverageOverweight$130.00Low
9/9/2022Bank of AmericaInitiated CoverageBuy$120.00Low
8/8/2022Piper SandlerLower TargetOverweight$162.00 ➝ $150.00Low
7/27/2022BTIG ResearchLower TargetBuy$190.00 ➝ $175.00Low
7/15/2022SVB LeerinkInitiated CoverageMarket Perform ➝ Market Perform$124.00Low
5/3/2022Wells Fargo & CompanyLower TargetOverweight$188.00 ➝ $158.00Low
5/2/2022Piper SandlerLower Target$181.00 ➝ $162.00Low
2/16/2022Wells Fargo & CompanyLower TargetOverweight$203.00 ➝ $188.00High
12/6/2021Wells Fargo & CompanyInitiated CoverageOverweight$203.00High
12/1/2021BTIG ResearchBoost TargetPositive ➝ Buy$210.00 ➝ $220.00Low
11/3/2021Craig HallumBoost TargetBuy$170.00 ➝ $205.00Low
11/3/2021Piper SandlerBoost TargetOverweight$188.00 ➝ $211.00Low
10/26/2021BTIG ResearchBoost TargetPositive ➝ Buy$175.00 ➝ $200.00High
7/27/2021BTIG ResearchReiterated RatingBuy$165.00 ➝ $151.49Low
6/23/2021Piper SandlerBoost TargetOverweight$152.00 ➝ $188.00Low
6/9/2021JPMorgan Chase & Co.Initiated CoverageNeutral$146.00Low
5/24/2021BTIG ResearchInitiated CoverageBuy$165.00Low
4/30/2021BenchmarkBoost TargetBuy$155.00 ➝ $160.00Low
4/30/2021Piper SandlerBoost TargetOverweight$147.00 ➝ $152.00Medium
3/22/2021BenchmarkBoost TargetBuy$140.00 ➝ $155.00Low
2/2/2021Piper SandlerUpgradeNeutral ➝ Overweight$86.00 ➝ $147.00N/A
1/20/2021BenchmarkBoost TargetBuy$125.00 ➝ $140.00Low
1/14/2021Craig HallumBoost TargetBuy$100.00 ➝ $142.00Low
12/9/2020BenchmarkBoost TargetBuy$100.00 ➝ $125.00High
12/8/2020Berenberg BankInitiated CoverageBuyHigh
12/3/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$95.00High
10/28/2020Craig HallumBoost TargetBuy$85.00 ➝ $100.00High
10/28/2020Wells Fargo & CompanyBoost TargetEqual Weight$74.00 ➝ $84.00Low
10/28/2020BenchmarkBoost TargetBuy$82.00 ➝ $100.00Low
10/28/2020Cantor FitzgeraldBoost TargetOverweight$90.00 ➝ $95.00Low
10/28/2020Piper SandlerBoost TargetNeutral$70.00 ➝ $86.00Low
7/29/2020Craig HallumLower TargetBuy$102.00 ➝ $85.00Medium
7/29/2020Cantor FitzgeraldBoost TargetOverweight$85.00 ➝ $90.00High
7/29/2020Piper SandlerLower TargetNeutral$76.00 ➝ $70.00High
7/6/2020StephensInitiated CoverageOverweight$90.00Medium
5/8/2020BenchmarkLower TargetBuy$96.00 ➝ $82.00High
5/8/2020Cantor FitzgeraldLower TargetOverweight$95.00 ➝ $85.00High
5/8/2020Piper SandlerLower TargetNeutral$88.00 ➝ $76.00High
2/7/2020Piper SandlerReiterated RatingHold$88.00Medium
2/7/2020Dougherty & CoBoost TargetBuy$92.00 ➝ $100.00High
1/8/2020Wells Fargo & CompanyBoost TargetEqual Weight$80.00 ➝ $85.00Low
12/11/2019Cantor FitzgeraldReiterated RatingOverweight$91.00 ➝ $95.00Low
11/21/2019Dougherty & CoBoost TargetBuy$90.00 ➝ $92.00Medium
10/25/2019SidotiSet TargetHold$82.00N/A
7/26/2019Craig HallumUpgradeHold ➝ Buy$85.00Low
4/26/2019BenchmarkBoost TargetBuy$82.00 ➝ $90.00Low
4/26/2019Craig HallumDowngradeBuy ➝ Hold$84.00Low
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/27/2023
  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 15 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
2/24/2024
  • 9 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 10 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 10 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Omnicell logo
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Read More

Today's Range

Now: $27.43
Low: $27.07
High: $28.35

50 Day Range

MA: $27.71
Low: $26.15
High: $29.24

52 Week Range

Now: $27.43
Low: $25.69
High: $77.14

Volume

486,690 shs

Average Volume

540,934 shs

Market Capitalization

$1.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Omnicell?

The following Wall Street sell-side analysts have issued stock ratings on Omnicell in the last year: Barclays PLC, Benchmark Co., BTIG Research, KeyCorp, Piper Sandler, StockNews.com, TheStreet, and Wells Fargo & Company.
View the latest analyst ratings for OMCL.

What is the current price target for Omnicell?

5 Wall Street analysts have set twelve-month price targets for Omnicell in the last year. Their average twelve-month price target is $42.20, suggesting a possible upside of 53.8%. KeyCorp has the highest price target set, predicting OMCL will reach $75.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $26.00 for Omnicell in the next year.
View the latest price targets for OMCL.

What is the current consensus analyst rating for Omnicell?

Omnicell currently has 1 sell rating, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OMCL, but not buy more shares or sell existing shares.
View the latest ratings for OMCL.

What other companies compete with Omnicell?

Other companies that are similar to Omnicell include Phreesia, AdaptHealth, Soleno Therapeutics, Brookdale Senior Living and Ironwood Pharmaceuticals. Learn More about companies similar to Omnicell.

How do I contact Omnicell's investor relations team?

Omnicell's physical mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company's listed phone number is (877) 415-9990 and its investor relations email address is [email protected]. The official website for Omnicell is www.omnicell.com. Learn More about contacing Omnicell investor relations.